Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 189 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
2. Cita con resumen
Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015;163:262-70. [Ref.ID 99499]
3. Cita con resumen
Anónimo. Celgene acquires Receptos for $7.2 billion. DIA Daily 2015;15 de julio:1. [Ref.ID 99253]
4. Cita con resumen
Anónimo. Védolizumab. Prescrire 2015;35:263-4. [Ref.ID 99125]
5. Cita con resumen
Anónimo. Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:86-8. [Ref.ID 98222]
6. Cita con resumen
Anónimo. Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:59-66. [Ref.ID 98172]
7.Tiene citas relacionadas Cita con resumen
Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandbom WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, Van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-18. [Ref.ID 97830]
8.Tiene citas relacionadas
Armuzzi A, Felice C. Etrolizumab in moderate-to-severe ulcerative colitis. Lancet 2014;384:285-6. [Ref.ID 97829]
9. Cita con resumen
Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014;160:704-11. [Ref.ID 97614]
10. Cita con resumen
Anónimo. Antibiotiques dans l'enfance et maladie intestinale inflammatoire?. Prescrire 2014;34:354-5. [Ref.ID 97563]
11. Cita con resumen
Anónimo. Golimumab (Simponi) for ulcerative colitis. Med Lett Drugs Ther 2014;56:25-6. [Ref.ID 97521]
12. Cita con resumen
Anónimo. Medicine to treat colitis, Crohn’s disease gets FDA nod. DIA Daily 2014:21 de mayo. [Ref.ID 97520]
14.Tiene citas relacionadas
Brotherton JML. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013;347:10. [Ref.ID 96427]
15.Tiene citas relacionadas
Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013;369:754-62. [Ref.ID 96021]
16.Tiene citas relacionadas
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, for the GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21. [Ref.ID 96018]
17.Tiene citas relacionadas
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G, Axler J, Kim H-J, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, for the GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710. [Ref.ID 96017]
18. Cita con resumen
Anónimo. Golimumab approved for ulcerative colitis. WHO Drug Information 2013;27:115. [Ref.ID 95814]
19. Cita con resumen
Anónimo. FDA approves Simponi to treat ulcerative colitis . FDA U.S. Food and Drug Administration 2013:15 de mayo. [Ref.ID 95446]
20. Cita con resumen
Anónimo. Budesonide (Uceris) for ulcerative colitis. Med Lett Drugs Ther 2013;55:23. [Ref.ID 95335]
Seleccionar todas
 
 1 a 20 de 189 siguiente >>